Immusoft Corp, Corporation just had published form D about $4.59 million equity financing. This is a new filing. Immusoft was able to fundraise $2.74 million so far. That is 59.64% of the round of financing. The total fundraising amount was $4.59 million. This form was filed on 2016-11-01. The reason for the financing was: unspecified. The fundraising still has about $1.85 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Immusoft is based in Washington. The filler’s business is not disclosed. The SEC form was filed by Matthew Scholz Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 454 N. 34Th Street, Seattle, Wa, Washington, 98103. Matthew Scholz is the related person in the form and it has address: C/O Immusoft Corporation, 454 N. 34Th Street, Seattle, Wa, Washington, 98103. Link to Immusoft Filing: 000168031116000004.
Analysis of Immusoft Offering
On average, firms in the not disclosed sector, sell 67.77% of the total offering size. Immusoft sold 59.64% of the offering. The fundraising is still open. The average investment offering size for companies in all industries in our database is $3.05 million. The offering was 10.16% smaller than the average of $3.05 million. Of course this should not be seen as negative. Companies get financed for a variety of needs and reasons. The minimum investment for this financing was set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Immusoft Also
The Form D signed by Matthew Scholz might help Immusoft Corp’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.